These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23319984)

  • 1. Health-related quality of life in Polish adolescents with Hymenoptera venom allergy treated with venom immunotherapy.
    Cichocka-Jarosz E; Brzyski P; Swiebocka E; Lange J; Tobiasz-Adamczyk B; Lis G; Jedynak-Wąsowicz U; Kulus M; Kaczmarski M; Małaczyńska T; Klajna-Kraluk B; Bręborowicz A; Kycler Z; Pietrzyk JJ
    Arch Med Sci; 2012 Dec; 8(6):1076-82. PubMed ID: 23319984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Health-related quality of life in children with Hymenoptera venom allergy treated with VIT and quality of life of their parents].
    Cichocka-Jarosz E; Tobiasz-Adamczyk B; Brzyski P; Lis G; Jedynak-Wasowicz U; Pietrzyk JJ; Ordyk B; Profus K; Lange J; Zagórska W; Kulus M; Swiebocka E; Kaczmarski M; Małaczyńska T; Swidzicka O; Breborowicz A; Kycler Z
    Przegl Lek; 2010; 67(12):1243-8. PubMed ID: 21591347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in children and adolescents after systemic sting reaction.
    Brzyski P; Cichocka-Jarosz E; Tarczoń I; Jedynak-Wąsowicz U; Tomasik T; Lis G
    Ann Agric Environ Med; 2019 Mar; 26(1):103-108. PubMed ID: 30922038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in parents of children and adolescents after systemic sting reactions.
    Cichocka-Jarosz E; Brzyski P; Tarczoń I; Jedynak-Wąsowicz U; Tomasik T; Lis G
    Ann Agric Environ Med; 2019 Jun; 26(2):315-321. PubMed ID: 31232065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.
    Eitel T; Zeiner KN; Assmus K; Ackermann H; Zoeller N; Meissner M; Kaufmann R; Kippenberger S; Valesky EM
    World Allergy Organ J; 2021 May; 14(5):100536. PubMed ID: 33995819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
    Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
    Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of venom immunotherapy on anxiety level of being re-stung].
    Sacha M; Czarnobilska E; Stobiecki M; Dyga W
    Przegl Lek; 2012; 69(12):1261-5. PubMed ID: 23750435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of venom immunotherapy: Evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy).
    Stock R; Fischer T; Aẞmus K; Zoeller N; Ackermann H; Kaufmann R; Meissner M; Valesky E
    World Allergy Organ J; 2021 Jan; 14(1):100496. PubMed ID: 33376576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-of-life in insect venom allergy: validation of the Turkish version of the "Vespid Allergy Quality of Life Questionnaire" (VQLQ-T).
    Sin BA; Öztuna D; Gelincik A; Gürlek F; Baysan A; Sin AZ; Aydın Ö; Mısırlıgil Z
    Springerplus; 2016; 5():583. PubMed ID: 27247880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
    J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.
    Oude Elberink JN; De Monchy JG; Van Der Heide S; Guyatt GH; Dubois AE
    J Allergy Clin Immunol; 2002 Jul; 110(1):174-82. PubMed ID: 12110838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
    Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R
    Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the quality of life in subjects with a history of severe anaphylactic reaction to the Hymenoptera venom.
    Nowak N; Bazan-Socha S; Pulka G; Pełka K; Latra P
    Pneumonol Alergol Pol; 2015; 83(5):352-8. PubMed ID: 26378996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rush Venom Immunotherapy in Children.
    Confino-Cohen R; Rosman Y; Goldberg A
    J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors in Hymenoptera venom allergy.
    Ruëff F; Kroth J; Przybilla B
    Allergol Select; 2017; 1(1):53-58. PubMed ID: 30402602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
    Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
    Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of 100 µg venom immunotherapy rush protocols in children compared to adults.
    Stoevesandt J; Hosp C; Kerstan A; Trautmann A
    Allergy Asthma Clin Immunol; 2017; 13():32. PubMed ID: 28706538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of hymenoptera venom allergy and venom immunotherapy.
    Bilò MB; Tontini C; Martini M; Corsi A; Agolini S; Antonicelli L
    Eur Ann Allergy Clin Immunol; 2019 Nov; 51(6):244-258. PubMed ID: 31594296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.